Genprex, Inc. Files 8-K: Corporate Details
Ticker: GNPX · Form: 8-K · Filed: Oct 24, 2024 · CIK: 1595248
Sentiment: neutral
Topics: corporate-filing, 8-K
Related Tickers: GNPX
TL;DR
Genprex filed an 8-K on 10/24/24, updating corporate info. Nothing major, just housekeeping.
AI Summary
Genprex, Inc. filed an 8-K on October 24, 2024, reporting other events and financial statements. The filing details the company's corporate structure, including its incorporation in Delaware and its principal executive offices located at 3300 Bee Cave Road, #650-227, Austin, TX 78746. The company's IRS Employer Identification Number is 90-0772347.
Why It Matters
This filing provides essential corporate information and updates for Genprex, Inc., which is important for investors and stakeholders to understand the company's structure and reporting status.
Risk Assessment
Risk Level: low — The filing is a routine 8-K reporting corporate information and does not appear to contain significant new business developments or financial risks.
Key Players & Entities
- Genprex, Inc. (company) — Registrant
- October 24, 2024 (date) — Filing Date
- Delaware (jurisdiction) — State of Incorporation
- 3300 Bee Cave Road, #650-227, Austin, TX 78746 (address) — Principal Executive Offices
- 90-0772347 (identifier) — IRS Employer Identification Number
- 512-537-7997 (phone_number) — Registrant's telephone number
FAQ
What is the exact name of the registrant as specified in its charter?
The exact name of the registrant is Genprex, Inc.
In which jurisdiction was Genprex, Inc. incorporated?
Genprex, Inc. was incorporated in Delaware.
What is the address of Genprex, Inc.'s principal executive offices?
The address of Genprex, Inc.'s principal executive offices is 3300 Bee Cave Road, #650-227, Austin, TX 78746.
What is the IRS Employer Identification Number for Genprex, Inc.?
The IRS Employer Identification Number for Genprex, Inc. is 90-0772347.
What is the registrant's telephone number, including area code?
The registrant's telephone number is (512) 537-7997.
Filing Stats: 1,225 words · 5 min read · ~4 pages · Grade level 16.5 · Accepted 2024-10-24 09:29:33
Key Financial Figures
- $0.001 — h registered Common Stock , par value $0.001 per share GNPX The Nasdaq Capital Ma
Filing Documents
- gnpx20241002_8k.htm (8-K) — 32KB
- 0001437749-24-031966.txt ( ) — 163KB
- gnpx-20241024.xsd (EX-101.SCH) — 3KB
- gnpx-20241024_def.xml (EX-101.DEF) — 11KB
- gnpx-20241024_lab.xml (EX-101.LAB) — 15KB
- gnpx-20241024_pre.xml (EX-101.PRE) — 11KB
- gnpx20241002_8k_htm.xml (XML) — 3KB
01 Other Events
Item 8.01 Other Events. On October 24, 2024, Genprex, Inc. ("Genprex" or the "Company") issued a press release announcing the Company has entered into a Sponsored Research Agreement ("SRA") with the University of Michigan Rogel Cancer Center to study TUSC2, the tumor suppressor gene used in Genprex's lead drug candidate, Reqorsa Gene Therapy (quaratusugene ozeplasmid), in combination with ALK-inhibitors in ALK-EML4 positive translocated lung cancer. The Company also announced its collaboration with ALK Positive, a non-profit patient-driven research organization dedicated to improving the life expectancy and quality of life for ALK-positive (ALK+) lung cancer patients. As a part of this collaboration, both Genprex and ALK Positive will share the cost of the SRA with the University of Michigan Rogel Cancer Center. The Company noted in its press release that as the Company further expands its research program to new tumor targets, REQORSA in combination with ALK-inhibitors could be a potential therapeutic treatment for ALK+ lung cancer. TUSC2 is a tumor suppressor gene that is frequently deleted in lung cancer. Research collaborators at the Rogel Cancer Center's Judith Tam ALK Lung Cancer Research Initiative presented positive preclinical data at the April 2024 American Association for Cancer Research Annual Meeting, reporting that REQORSA induced apoptosis in alectinib resistant EML4-ALK positive non-small cell lung cancer ("NSCLC") cell lines. Alectinib is an ALK-inhibitor commonly used to treat patients with ALK rearrangements such as EML4-ALK positive NSCLCs. Researchers found that overexpressing TUSC2 using REQORSA treatment in ALK+ lung cancer cell lines inhibited the ability of the cells to form colonies. Ultimately, the study found that the use of REQORSA or a TUSC2-containing plasmid to overexpress TUSC2 in ALK+ NSCLC cell lines was effective in decreasing cell growth and proliferation through the activation of apoptotic pathways. Researchers believe the re
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. GENPREX, INC. Date: October 24, 2024 By: /s/ Ryan Confer Ryan Confer Chief Executive Officer and Chief Financial Officer (Principal Executive Officer and Principal Financial and Accounting Officer)